CARE TEAM FORUM®

WHAT LIES BENEATH:
Current and Emerging Treatments for Prurigo Nodularis

Provided by RMEI Medical Education, LLC

RMEI MEDICAL EDUCATION FOR BETTER OUTCOMES

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.







Kowalski EH, et al. *Clin Cosmet Investig Dermatol*. 2019;12:163-172



Mullins TB, et al. Prurigo Nodularis. [Updated 2022]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK459204/

Core Symptoms

Presence of firm, nodular lesions



Pruritis lasting ≥6 weeks



History and/or signs of repeated scratching, picking, or rubbing

Additional Common Features



- Symmetrical distribution of nodules
- Rarely affected areas: face, palms, soles, scape, and genitals
- Additional lesions induced by scratching may be present
- Burning, stinging, pain
- Impaired QoL, including sleep deprivation
- Associated comorbidities (renal/liver/thyroid dysfunction, diabetes, HIV, HBV/HCV, malignancy)

Elmariah S, et al. *J Am Acad Dermatol.* 2021;84(3):747-760.

Pathophysiology

Neuroimmune Dysregulation



Increased Th2 Cytokines and Inflammatory Mediators in Lesional Skin

IL-4

IL-13

IL-31

Others

Induce itch, inflammation, and perpetuate the itch-scratch cycle

Conventional Management

Neuronal

- Cannabinoids†
- Thalidomide
- NK_1 Antagonists
- High-dose gabapentinoids
- Antidepressants (SNRIs→ SSRIs→ TCAs)
- Low-dose gabapentinoids
- Topical ketamine/amitriptyline/lidocaine
- Topical capsaicin

Immunological

- Mycophenolate Mofetil†
- Azathioprine
- Cyclosporine
- Methotrexate
- Narrowband UVB/PUVA Phototherapy
- Intralesional Corticosteroids*/cryotherapy
- Topical Calcipotriol
- Topical Calcineurin Inhibitors
- Topical Corticosteroids

*For ≤10 lesions
†Helpful in chronic pruritis, but data is lacking in prurigo nodularis

Adapted from: Elmariah S, et al. *J Am Acad Dermatol.* March 2021;84(3):747-760.

Dupilumab in Prurigo Nodularis

Dually blocks Th2 cytokines IL-4 and IL-13

LIBERTY-PN PRIME Phase 3 Trials

CARE TEAM FORUM®

PRIME (N=151) [1]

Clinically Meaningful **Reduction in Itch** from Baseline



Percentage of Patients Achieving **Clear Skin**



PRIME 2 (N=160)[2]

Clinically Meaningful **Reduction in Itch** from Baseline



Percentage of Patients Achieving **Clear Skin**



In both trials, subjects receiving dupilumab showed improved QoL. No new safety concerns were detected.

1. NCT04183335.
2. Gil Yosipovitch, et al. LIBERTY-PN PRIME2. Presented at AAD Annual Meeting. Late Breaking Abstracts; 26 Mar 2022: Boston, MA.

LIBERTY-PN PRIME Phase 3 Trials

CARE TEAM FORUM®

PRIME (N=151) [1]

Clinically Meaningful **Reduction in Itch** from Baseline



Percentage of Patients Achieving **Clear Skin**



PRIME 2 (N=160)[2]

Clinically Meaningful **Reduction in Itch** from Baseline





Percentage of Patients Achieving **Clear Skin**



In both trials, subjects receiving dupilumab showed improved QoL. No new safety concerns were detected.

1. NCT04183335.
2. Gil Yosipovitch, et al. LIBERTY-PN PRIME2. Presented at AAD Annual Meeting. Late Breaking Abstracts; 26 Mar 2022: Boston, MA.

Emerging Therapies

Nemolizumab

Humanized mAb against the **IL-31 receptor A**

OLYMPIA-2 (N=70)[1]

Percent change from baseline in the mean peak score for pruritus

Week 4



Vixarelimab

Human mAb against oncostatin M receptor beta (OSMRβ). Binding to OSMRβ inhibits **IL-31 and OSM signaling.**

Phase 2a (N=49)[2]

LSM change from baseline in weekly-average WI-NRS

Week 8



Percent change achieving a PN-IGA score of 0/1

Week 8



LSM, least squares mean; PN-IGA, Prurigo Nodularis – Investigator's Assessment

1. Ständer S, et al. *N Engl J Med.* 2020;382(8):706-716. 2. NCT03816891.